{
    "clinical_study": {
        "@rank": "137988", 
        "acronym": "B-YOND", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 (BYL719)", 
                "arm_group_type": "Experimental", 
                "description": "BYL719 plus Tamoxifen and Goserelin (Arm 1)"
            }, 
            {
                "arm_group_label": "Arm 2 (BKM120)", 
                "arm_group_type": "Active Comparator", 
                "description": "Buparlisib plus Tamoxifen and Goserelin (Arm 2)"
            }, 
            {
                "arm_group_label": "Arm 3 (Control)", 
                "arm_group_type": "Active Comparator", 
                "description": "Tamoxifen and Goserelin (Arm 3)"
            }
        ], 
        "brief_summary": {
            "textblock": "Based on the evidence acquired in the post-menopausal setting with everolimus and on\n      pre-clinical evidences supporting the investigation of PI3K inhibitors, such as BYL719 and\n      buparlisib, in combination with endocrine therapy in hormone receptor-positive MBC, the\n      purpose of this phase II trial is to assess the safety and the clinical anti-tumor activity\n      of tamoxifen plus goserelin acetate in combination with BYL719 or buparlisib vs tamoxifen\n      plus goserelin acetate in premenopausal hormone receptor-positive advanced breast cancer\n      patients, through a randomized open label 3-arm study."
        }, 
        "brief_title": "A Phase II Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pre-menopausal Breast Cancer", 
            "PI3K Pathway Inhibition"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient has histologically and/or cytologically confirmed diagnosis of breast cancer\n\n          2. Patient has radiological or objective evidence of inoperable locally advanced or\n             metastatic breast cancer\n\n          3. Patient has HER2-negative breast cancer (based on most recently analyzed tumor\n             sample)\n\n          4. Patient has ER positive and/or PgR positive breast cancer by local laboratory testing\n\n          5. Patient is premenopausal. Premenopausal status is defined as either:\n\n               1. patient had last menstrual period within the last 12 months, OR\n\n               2. if on tamoxifen within the past 3 months, with a plasma estradiol \u226510 pg/mL and\n                  FSH \u226440 IU/l or in the premenopausal range, according to local laboratory\n                  definition , OR\n\n               3. in case of chemotherapy induced amenorrhea, with a plasma estradiol \u226510 pg/mL)\n                  and/or FSH \u226440 IU/l or in the premenopausal range according to local laboratory\n                  definition.\n\n          6. Patient has no previous history of endocrine therapy in the metastatic setting.\n\n             Note:\n\n               -  Patients who received endocrine therapy with duration less than 3 weeks and\n                  discontinued for a reason other than suspicious or evidence of disease\n                  progression are eligible\n\n               -  Adjuvant treatment with tamoxifen is allowed. In this setting, prior use of\n                  LH-RH agonist/antagonist is permitted only if disease recurrence occurred after\n                  at least 12 months of last dose of LH-RH agonist/antagonist was received.\n\n               -  Patients who were already established on bisphosphonate therapy may continue on\n                  bisphosphonates.\n\n          7. Patient has received \u22641 prior chemotherapy line for MBC\n\n          8. For patient who received prior systemic therapy, radiological or objective evidence\n             of recurrence or progression on or after the last systemic therapy is needed\n\n          9. Patient must have as per RECIST 1.1:\n\n               -  measurable disease or\n\n               -  non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of\n                  measurable disease.\n\n         10. Patient has adequate bone marrow and organ function as defined by the following\n             laboratory values:\n\n         11. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status \u2266 2 which\n             the investigator believes is stable at the time of screening.\n\n         12. Patient has negative serum pregnancy test (\u03b2-hCG) within 72 hrs before starting study\n             treatment.\n\n        Exclusion criteria\n\n          1. Patient is post-menopausal.\n\n          2. Patient has received previous endocrine treatments in the metastatic setting.\n\n          3. Patient has received previous treatment with PI3K inhibitors, AKT inhibitors, mTOR\n             inhibitors\n\n          4. Patient has received more than one chemotherapy line for metastatic disease\n\n          5. Patient has symptomatic CNS metastases\n\n          6. Patient who has received wide field radiotherapy \u2266 4 weeks or limited field radiation\n             for palliation \u2266 2 weeks prior to starting study drug or who have not recovered to\n             grade 1 or better from related side effects of such therapy (with exception of\n             alopecia alopecia)\n\n          7. Patient has not recovered to grade 1 or better (except alopecia) from related side\n             effects of any prior antineoplastic therapy\n\n          8. Patient is currently receiving increasing or chronic treatment (> 5 days) with\n             corticosteroids or another immunosuppressive agent, as chronic administration of\n             corticosteroids (> 5 days) can induce CYP3A4\n\n          9. Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for\n             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight\n             heparin (LMWH), or fondaparinux is allowed\n\n         10. Patient is currently receiving treatment with drugs known to be moderate or strong\n             inhibitors or inducers of isoenzyme CYP3A. The patient must have discontinued strong\n             inducers for at least one week and must have discontinued strong inhibitors before\n             the treatment phase is initiated.\n\n         11. Patient has a score \u2267 12 on the PHQ-9 questionnaire\n\n         12. Patient selects a response of \"1, 2 or 3\" to question number 9 on the PHQ-9\n             questionnaire regarding potential for suicidal thoughts or ideation (independent of\n             the total score of the PHQ-9)\n\n         13. Patient has a GAD-7 mood scale score \u2267 15\n\n         14. Patient has a medically documented history of or active major depressive episode,\n             bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history\n             of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to\n             self or others) or patients with active severe personality disorders (defined\n             according to DSM- IV) are not eligible.\n\n         15. Patient has \u2267 Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety\n\n         16. Patient has active cardiac disease or a history of cardiac dysfunction\n\n         17. Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by\n             Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)\n\n         18. Patient has any of the following cardiac conduction abnormalities\n\n               1. Ventricular arrhythmias except for benign premature ventricular contractions\n\n               2. Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled\n                  with medication\n\n               3. Conduction abnormality requiring a pacemaker\n\n               4. Other cardiac arrhythmia not controlled with medication\n\n               5. Patient has a QTcF > 480 msec on the screening ECG (using the QTcF formula)\n\n         19. Patient is currently receiving treatment with medication that has a known risk to\n             prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be\n             discontinued or switched to a different medication prior to randomization."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "192", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058381", 
            "org_study_id": "CBYL719XIC01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1 (BYL719)", 
                "description": "BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Arm 1 only).", 
                "intervention_name": "BYL719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2 (BKM120)", 
                "description": "Buparlisib 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Arm 2 only)", 
                "intervention_name": "BKM120", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 3 (Control)", 
                "description": "Tamoxifen 20 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 in all three arms. Goserelin will be administered in all three arms at a dose of 3.6 mg s.c. on day 1 cycle 1 and every 28 days.", 
                "intervention_name": "Control", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tamoxifen", 
                "Goserelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "410-769"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "120-752"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "135-710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bundang", 
                        "country": "Korea, Republic of", 
                        "state": "Seongnam", 
                        "zip": "463-707"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "738-736"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuei-Shan Chiang", 
                        "country": "Taiwan", 
                        "state": "Taoyuan/ Taiwan ROC", 
                        "zip": "33305"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changhua", 
                        "country": "Taiwan", 
                        "zip": "500"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Taipei City", 
                        "country": "Taiwan", 
                        "zip": "23561"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niaosong Township", 
                        "country": "Taiwan", 
                        "zip": "83301"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "407"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiang Mai", 
                        "country": "Thailand", 
                        "zip": "50200"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Hong Kong", 
                "Korea, Republic of", 
                "Taiwan", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Randomized Study of the Combination of Tamoxifen Plus Goserelin Acetate With BYL719 or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Taiwan: Institutional Review Board", 
                "Korea: Food and Drug Administration", 
                "China: Food and Drug Administration", 
                "Thailand: Food and Drug Administration", 
                "Hong Kong: Department of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate and compare the preliminary efficacy of\nBYL719 in combination with tamoxifen plus goserelin acetate versus tamoxifen plus goserelin acetate AND\nbuparlisib in combination with Tamoxifen plus goserelin acetate vsTamoxifen plus goserelin acetate in premenopausal hormone receptor-positive locally advanced or MBC patients.", 
            "measure": "Proportion of patients who are alive without progression at 9 months from the date of randomization", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058381"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate and compare the anti-tumor activity of BYL719/buparlisib in combination with tamoxifen plus goserelin vs tamoxifen plus goserelin", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Progression-free survival (PFS) is defined as the time from the date of randomization to the date of the first documented progressive disease (PD) or death due to any cause.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Best overall response for each patient is determined from the sequence of overall (lesion) responses according to the following rules:\nCR = at least two determinations of CR at least 4 weeks apart before progression\nPR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR)\nSD = at least one SD assessment (or better) > 5 weeks after randomization date (and not qualifying for CR or PR).", 
                "measure": "Clinical benefit (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To evaluate and compare the impact of BYL719/buparlisib in combination with tamoxifen plus goserelin vs tamoxifen plus goserelin on patient-reported health status and impact on work", 
                "measure": "Index score from the EQ-5D-5L; and WPAI-GH scores for work time missed, impairment while working, overall work impairment, and activity impairment", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To determine the safety and tolerability of BYL719/ buparlisib in combination with tamoxifen plus goserelin vs tamoxifen plus goserelin in premenopausal hormone receptor-positive locally advanced and MBC patients", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "BYL719/buparlisib: plasma concentrations and PK: CMAX", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "BYL719/buparlisib: plasma concentrations and PK: AUC0-24", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "BYL719/buparlisib: plasma concentrations and PK: TMAX", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "BYL719/buparlisib: plasma concentrations and PK: AUC0Inf", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "BYL719/buparlisib: plasma concentrations and PK: AUC0-t", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}